Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01032993 |
|
Recruitment Status :
Completed
First Posted : December 16, 2009
Results First Posted : January 23, 2017
Last Update Posted : January 23, 2017
|
Sponsor:
Catherine Buettner
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by (Responsible Party):
Catherine Buettner, Beth Israel Deaconess Medical Center
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study will evaluate whether a dietary supplement, coenzyme Q10 (CoQ10), will improve muscle symptoms, such as muscle aches, pains, cramps, and/or weakness, which are experienced by some individuals who use statin medications.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pain Weakness Cramps Myalgia or Myositis Nos HMG COA Reductase Inhibitor Adverse Reaction | Dietary Supplement: Coenzyme Q10 Other: Placebo | Phase 2 Phase 3 |
This study will recruit individuals who have had muscle symptoms while using a statin. During the first part of the study, volunteers will be given a statin medication to see if their muscle symptoms return. Those who experience muscle symptoms on this statin rechallenge will be invited to continue in the second part of the trial, in which participants will be randomly assigned to receive either CoQ10 or a placebo (sugar pill) to take with statin medication. We hypothesize that those who receive CoQ10 will experience an improvement in their muscle symptoms compared to those who receive placebo, and, secondarily, that those who receive CoQ10 will be more likely to continue taking the statin medication.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 68 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms |
| Study Start Date : | December 2009 |
| Actual Primary Completion Date : | May 2016 |
| Actual Study Completion Date : | May 2016 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Idiopathic inflammatory myopathy
Drug Information available for:
Ubidecarenone
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Coenzyme Q10
600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
|
Dietary Supplement: Coenzyme Q10
300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks |
|
Placebo Comparator: Placebo
Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
|
Other: Placebo
Placebo (three chewable tablets) 2 times daily for 4 weeks |
Primary Outcome Measures :
- Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use [ Time Frame: 4 weeks ]Clinically significant pain reduction was defined, a priori, as a reduction > 1.5 points on the Brief Pain Inventory-Severity Scale (BPI-SS), range: 0 to 10
Secondary Outcome Measures :
- Continuation of Statin [ Time Frame: 4 weeks ]Adherence of statin use was defined a priori as participant using Simvastatin 20 mg /day at the end of 4 weeks and having used >85% of statin doses.
- Percentage of Participants With Improvement in Disability Related to Muscle Pain [ Time Frame: 4 weeks ]Disability improvement was based on patient report of improvement they felt was meaningful to them
- Percentage of Participants With Adverse Effects [ Time Frame: 4 weeks ]serious adverse effects and possible side effects were tracked through all phases of the study by participant interview and checklist at each visit, up to 4 weeks.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Patients with a history of muscle symptoms (such as aches, pains, cramps and/or weakness) while taking a statin drug that persisted for at least 2 weeks on a statin
Exclusion Criteria:
- Plasma creatine kinase levels > 3 times the upper normal limit
- Liver enzymes, alanine transferase (ALT) or aspartate transferase (AST) > 2 times the upper normal limit
- Pregnancy or breastfeeding (a contraindication for statin use)
- Severe renal impairment, defined as glomerular filtration rate (GFR) < 30 ml/min/1.73 m2
- Bleeding disorder, current use of warfarin, an international normalized ratio (INR) greater than 1.5, or a platelet count less than 100,000 mm3
- Contraindication to strength testing, including myocardial infarction, unstable angina, or revascularization procedure within the past six weeks, a history of brain aneurysm or stroke
- Chest or abdominal surgery within the past six weeks
- Severe persistent pain related to other causes
- Unable to complete self-administered questionnaires, or unable to read or converse in English
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01032993
Locations
| United States, Massachusetts | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States, 02215 | |
Sponsors and Collaborators
Catherine Buettner
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Investigators
| Principal Investigator: | Catherine Buettner, MD, MPH | Beth Israel Deaconess Medical Center |
| Responsible Party: | Catherine Buettner, Physician, Beth Israel Deaconess Medical Center |
| ClinicalTrials.gov Identifier: | NCT01032993 History of Changes |
| Other Study ID Numbers: |
K23AR055664 ( U.S. NIH Grant/Contract ) K23AR055664 ( U.S. NIH Grant/Contract ) |
| First Posted: | December 16, 2009 Key Record Dates |
| Results First Posted: | January 23, 2017 |
| Last Update Posted: | January 23, 2017 |
| Last Verified: | November 2016 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | No consent for sharing IPD from trial participants was obtained when this clinical trial began |
Keywords provided by Catherine Buettner, Beth Israel Deaconess Medical Center:
|
CoQ10 Statins Myalgia Muscle Pain Muscle Weakness |
Additional relevant MeSH terms:
|
Myositis Myalgia Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Musculoskeletal Pain Pain Neurologic Manifestations Signs and Symptoms Hydroxymethylglutaryl-CoA Reductase Inhibitors Coenzyme Q10 |
Ubiquinone Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Lipid Regulating Agents Micronutrients Growth Substances Physiological Effects of Drugs Vitamins |